The report highlights those generic drugs that are at the risk of facing shortages due to CGMP issues faced by a prominent player in that drug segment. 

It also offers product opportunities for generic companies to target based on these potential shortages

The report lists the PTE petitions Filed, Accepted / Denied / Withdrawn in a given quarter. This is also integrated into our Para IV Insights database to ensure that our generic launch timelines become even more accurate.